WILMINGTON, Mass., March 25, 2019 /PRNewswire/ -- CutisPharma, Inc. announced today the commercial availability of FIRST-Atenolol grape-flavored oral solution compounding kit. FIRST-Atenolol provides pharmacists with a convenient, high-quality, standardized way to compound an oral liquid Atenolol solution for patients who are not otherwise served by commercially available therapies, such as those who are unable to swallow solid oral dosing formulations.
"We are pleased to announce that, effective today, FIRST-Atenolol is available to all pharmacies in the United States," said Mike Radice, CutisPharma's Chief Commercial Officer. "The addition of FIRST-Atenolol to our overall portfolio of FIRST Unit-of-Use Compounding Kits has been widely anticipated by our customers. This represents the second new addition to the family of FIRST Kits launched this year, after FIRST-Metoprolol, providing pharmacists with an expanded range of high-quality alternatives to traditionally compounded oral liquid suspensions and solutions."
FIRST-Atenolol is now available in 2 mg/mL 300mL and 10 mg/mL 150 mL strengths to allow additional flexibility for a variety of patient needs.
CutisPharma, Inc., based in Wilmington, MA, is a privately held, specialty pharmaceutical company that has been the industry leader for over 20 years in providing innovative solutions to pharmacists. CutisPharma's FIRST Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by other commercially available therapies. In April 2018, CutisPharma announced the launch of FIRVANQ® (vancomycin hydrochloride for oral solution), the only FDA-approved vancomycin oral liquid therapy for patients with Clostridium difficile-associated diarrhea. For more information, visit www.cutispharma.com, www.firvanq.com or contact us at [email protected].
SOURCE CutisPharma, Inc.